By: IPP Bureau
Last updated : August 20, 2026 6:42 pm
The company also turned profitable at the standalone level, reporting PAT of Rs. 12 crore, against a loss of Rs. 3 crore in Q1 FY26
Orchid Pharma has reported a strong improvement in its first-quarter performance for FY27, with revenue rising 16 percent and EBITDA nearly tripling year-on-year, following the integration of Dhanuka Laboratories into the company.
Standalone revenue from operations increased to Rs. 304 crore in Q1 FY27, compared with Rs. 263 crore in the corresponding quarter of FY26. EBITDA surged 178 percent to Rs. 25 crore, from Rs. 9 crore, lifting the EBITDA margin to 8 percent from 3 percent.
The company also turned profitable at the standalone level, reporting PAT of Rs. 12 crore, against a loss of Rs. 3 crore in Q1 FY26. Gross margin improved to 33 percent from 30 percent.
On a consolidated basis, Orchid Pharma reported total income of Rs. 306 crore for the quarter. Profit for the period stood at Rs. 3.22 crore, compared with a loss of Rs. 5.69 crore in Q1 FY26.
Consolidated basic and diluted EPS stood at Rs. 0.54, compared with a loss per share of Rs. 0.95 in the year-ago period.
The quarter marks an important phase in Orchid Pharma's integration with the Dhanuka Group. The amalgamation of Dhanuka Laboratories Limited with Orchid Pharma became effective on July 10, 2026, under a scheme sanctioned by the National Company Law Tribunal, with an appointed date of April 1, 2024.
Dhanuka Laboratories, established in 1998, has a strong presence in cephalosporin antibiotics across emerging markets and operates two API manufacturing facilities.
Following the merger, Orchid has retrospectively revised its FY25 and FY26 financials to reflect the combined entity.
Orchid Pharma continues to position itself as an integrated anti-infective pharmaceutical platform, with expertise spanning cephalosporins, APIs and finished dosage formulations.